Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Company Data

Name Bright Minds Biosciences Inc. - common stock

Company Bright Minds Biosciences Inc.

Symbol DRUG

Website https://brightmindsbio.com

Primary Exchange

NASDAQ

ISIN CA10919W4056

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Ian McDonald

Market Capitalization 301 Mio

Country Canada

Currency USD

Employees -

Address 1500 – 1055 West Georgia Street, V6E 4N7 New York City

IPO Date 2021-03-22

Ticker Symbols

Name	Symbol
CSE LISTED	DRUG.CN
NASDAQ	DRUG

More Shares

Investors who hold Bright Minds Biosciences Inc. - common stock also have the following shares in their portfolio:

PAN ANDEAN MINERALS Share

UBS AG LEADING GLOBAL TRENDS ZERTIFIKAT Zertifikat

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog